In today’s ACT Brief, we cover the FDA approval of oral Wegovy based on Phase III OASIS 4 results, recap the most-read ...

Review the performance, engagement, and satisfaction metrics sponsors and CROs should track to determine whether operational ...

If we can use AI or AI agents to automate those workflows, you can still run the same process, particularly as it relates to ...

Persistent recruitment delays, high dropout rates, and missed timelines continue to slow global clinical trials, while data show that sub-Saharan Africa offers a largely untapped opportunity with ...

In today’s ACT Brief, we examine why fragmented data systems continue to slow life sciences research, review how sponsor ...

Learn how clinical operations leaders can build technology adoption, transform workflows, and cultivate digitally savvy ...

Generative AI adoption, regulatory scrutiny, DEI policy shifts, real-world evidence, and rare disease economics emerged as key themes across these most-read Applied Clinical Trials articles shaping ...

Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, outperforming placebo. The FDA approval of oral semaglutide marks the first GLP-1 pill for chronic weight management, ...

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...

In today’s ACT Brief, we examine how sponsors are reassessing new engagement technologies to avoid increasing site burden, ...

In today’s ACT Brief, we look at new evidence showing how targeted training can build research readiness at community cancer ...